Essential Partners’s Filana Therapeutics FLNA Stock Holding History

Essential Partners’s Portfolio FLNA Stock Details FLNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-48	Closed	-$87	–	2770
2025 Q2	$87	Buy	+48	New	+$85	﹤0.01%	2084

Other funds holding FLNA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

GMT Capital Atlanta, Georgia $1.92B AUM 70.51% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Essential Partners's FLNA Position: Q3 2025 in Review

Essential Partners sold out of Filana Therapeutics (FLNA) in Q3 2025, closing a stake of 48 shares — an estimated $87 sold.

Essential Partners first reported a position in FLNA in Q2 2025 and held it in 1 quarter. The position peaked at $87 in Q2 2025. 103 funds tracked by Wall St. Rank hold FLNA as of Q3 2025.

Essential Partners reported no remaining Filana Therapeutics position as of Q3 2025 after selling out during the quarter.
Essential Partners sold 48 Filana Therapeutics shares in Q3 2025, an estimated $87.
Essential Partners first reported a position in Filana Therapeutics in Q2 2025 and held it in 1 quarter.
Essential Partners's Filana Therapeutics position peaked at $87 in Q2 2025.
103 funds tracked by Wall St. Rank held Filana Therapeutics as of Q3 2025.

Based on Essential Partners's 13F filing for Q3 2025, filed 21 May 2026.